These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26289223)

  • 21. Advances in hepatitis C therapies.
    Mariño Z; Lens S; Gambato M; Forns X
    Expert Opin Pharmacother; 2015; 16(13):1929-43. PubMed ID: 26219918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C genotype 1.
    Foster GR; De Silva S
    Curr Opin Infect Dis; 2014 Dec; 27(6):535-9. PubMed ID: 25304394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C.
    Kumar S; Jacobson IM
    J Hepatol; 2014 Nov; 61(1 Suppl):S91-7. PubMed ID: 25443349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir.
    Collins JM; Raphael KL; Terry C; Cartwright EJ; Pillai A; Anania FA; Farley MM
    Clin Infect Dis; 2015 Oct; 61(8):1304-6. PubMed ID: 26082511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
    D'Ambrosio R; Aghemo A; Colombo M
    Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C therapy: Looking toward interferon-sparing regimens.
    Au TH; Destache CJ; Vivekanandan R
    J Am Pharm Assoc (2003); 2015; 55(2):e72-84; quiz e85-6. PubMed ID: 25658389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
    Prescrire Int; 2015 Dec; 24(166):285-9. PubMed ID: 26788571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chronic hepatitis C infection--eradication of the virus].
    Ben Ari Z
    Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New hepatitis C therapies: the toolbox, strategies, and challenges.
    Pawlotsky JM
    Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
    Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current therapy for chronic hepatitis C: The role of direct-acting antivirals.
    Li G; De Clercq E
    Antiviral Res; 2017 Jun; 142():83-122. PubMed ID: 28238877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials.
    Ferreira VL; Tonin FS; Assis Jarek NA; Ramires Y; Pontarolo R
    Clin Drug Investig; 2017 Jul; 37(7):635-646. PubMed ID: 28409482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second generation direct-acting antivirals - Do we expect major improvements?
    Feld JJ; Foster GR
    J Hepatol; 2016 Oct; 65(1 Suppl):S130-S142. PubMed ID: 27641983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chronic Hepatitis C - Therapeutic Options in 2016].
    Zachoval R; Jung MC
    MMW Fortschr Med; 2016 Jun; 158 Suppl 1():54-7. PubMed ID: 27259905
    [No Abstract]   [Full Text] [Related]  

  • 38. Vedroprevir in the management of hepatitis C virus infection.
    Abutaleb A; Kottilil S
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1399-1402. PubMed ID: 29053394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.
    Kwo PY; Puenpatom A; Zhang Z; Hui SL; Kelley AA; Muschi D
    PLoS One; 2019; 14(8):e0218759. PubMed ID: 31437170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C Virus and Antiviral Drug Resistance.
    Kim S; Han KH; Ahn SH
    Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.